Lexeo Therapeutics Inc. C... (LXEO)
NASDAQ: LXEO
· Real-Time Price · USD
6.62
-0.08 (-1.19%)
At close: Oct 03, 2025, 3:59 PM
6.49
-1.96%
After-hours: Oct 03, 2025, 07:14 PM EDT
-1.19% (1D)
| Bid | 5.97 |
| Market Cap | 219.76M |
| Revenue (ttm) | 1.94M |
| Net Income (ttm) | -114.17M |
| EPS (ttm) | -3.21 |
| PE Ratio (ttm) | -2.06 |
| Forward PE | -3.42 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.16 |
| Volume | 446,547 |
| Avg. Volume (20D) | 515,211 |
| Open | 6.69 |
| Previous Close | 6.70 |
| Day's Range | 6.33 - 6.87 |
| 52-Week Range | 1.45 - 11.72 |
| Beta | 1.67 |
| Ex-Dividend Date | n/a |
About LXEO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LXEO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LXEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+50.92%
Lexeo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
10 months ago
-0.65%
Lexeo Therapeutics shares are trading higher. Leerink Partners maintained an Outperform rating on the stock.
5 months ago · seekingalpha.com
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program AdvancementLexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy. Pivotal LXEO regi...